Introduction
Numerous demonstrations of clinical efficacy with targeted therapies in a diverse range of cancer types have cemented molecularly targeted therapies as a major pillar in the treatment of many advanced solid-tumor and hematologic malignancies. For advanced non-small-cell lung cancers (NSCLCs) with certain activating mutations in the EGFR gene, first-and second-generation EGFR-directed tyrosine-kinase inhibitors (TKIs), including gefitinib, erlotinib, and afatinib 1,2 have supplanted platinumcontaining chemotherapy regimens as first-line therapy, marking a major paradigm shift in the treatment of NSCLC. Unfortunately, despite initial clinical and radiological responses, resistance to first-and second-generation EGFR TKIs invariably develops, with median progression-free survival of 9-16 months [3] [4] [5] [6] and approximately 60% of patients developing resistance mediated by drug-induced selection of tumor-cell clones harboring a threonine-methionine amino-acid substitution at position 790 (T790M) of EGFR, which is the putative gatekeeper residue. 7 The current review focuses on EGFR T790M. We first outline the treatment of EGFR-mutant NSCLC with first-and second-generation EGFR TKIs and the discovery of EGFR T790M as a dominant resistance mechanism to first-and second-generation EGFR TKI treatment. We then discuss mechanisms of resistance mediated by EGFR T790M and the development of novel third-generation EGFR TKIs targeting EGFR T790M. Next, we introduce novel methods for detecting EGFR T790M, along with appropriate workflows for incorporating molecular testing into clinical management.
Treatment of EGFR-mutant NSCLC with first-and second-generation EGFR TKIs
EGFR is a cell-surface receptor belonging to the ErbB family of receptor TKs that also includes ErbB2/Her2/Neu, ErbB3/ Her3, and ErbB4/Her4. The binding of cognate ligands, such as EGF and TGFα, induces a conformational change in EGFR that facilitates receptor homo-or heterodimer formation, in which the C-terminal lobe of one kinase domain of the asymmetric dimer complex plays a role analogous to that of cyclin in activated cyclin-dependent kinase complexes. 8, 9 Subsequently, activated EGFR can phosphorylate a range of substrates that results in the activation of multiple important downstream-signaling pathways within the cell, including the RAS-RAF-MEK-ERK pathway and the PI3K-AKTmTOR pathway, promoting cell proliferation and cell survival, respectively. With certain activating EGFR mutations, EGFR TK activity is permanently switched on, even in the absence of cognate ligands, through an intrinsic tendency to form asymmetric dimers, in which the C-terminal lobe of one kinase domain associates with the N-terminal lobe of a neighboring kinase domain, inducing an active conformation by orientating the regulatory C-helix to its inward position 10 and resulting in inappropriate constitutive activation of oncogenic downstream-signaling pathways.
Tumor-associated EGFR mutations are present in approximately 10%-20% of NSCLC patients, 1,2 with higher incidence in younger females, nonsmokers, and adenocarcinoma histology, occurring as frequently as 30%-50% in neversmokers with lung adenocarcinoma. 11 These mutations most commonly occur within EGFR exons 18-21, which encode a critical portion of the EGFR-kinase domain, and usually do not occur concurrently with other NSCLC oncogenic mutations, such as KRAS mutations and ALK-gene rearrangements. Approximately 90% of these mutations are EGFR exon 19 deletions or exon 21 L858R point mutations, 12 which increase the kinase activity of EGFR, leading to hyperactivation of downstream prosurvival signaling pathways, such as PI3K-AKT-mTOR and RAS-RAF-MEK-ERK, 13 as well as induction of cyclin D1 expression.
14 Through negativefeedback regulation, dual-specificity phosphatases, such as DUSP4 and DUSP6, can dampen excessive MAP-kinase signal transduction, while PHLDA1/2 can mitigate AKT activation. [15] [16] [17] In addition, upregulation of the BH3-only polypeptide BIM correlates with gefitinib-induced apoptosis in gefitinib-sensitive EGFR-mutant lung cancer cells. 18 Small-molecule adenosine triphosphate (ATP)-mimetic first-generation EGFR TKIs, such as gefitinib and erlotinib, inhibit EGFR TK activity by reversibly binding to the ATP-binding site of the receptor, while afatinib, a secondgeneration EGFR TKI, binds to the site irreversibly at aminoacid residue C797 at the cost of more severe epithelium-based toxicities (eg, rash, diarrhea) associated with increased binding to wild-type EGFR. In 2009, a pivotal Phase III study demonstrated superiority of gefitinib over carboplatinpaclitaxel as initial treatment for EGFR-mutated lung adenocarcinoma. The study was conducted among nonsmokers or former light smokers in East Asia with 12-month rates of progression-free survival of 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel. In the subgroup of 261 patients with EGFR mutations, response rates were doubled and progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (HR for progression or death 0.48, 95% CI 0.36-0.64; P<0.001), establishing frontline EGFR TKI therapy as the optimal choice for this group of patients and highlighting the critical need for molecular testing in patients with advanced NSCLC. 3 Since then, these results have been replicated multiple times with gefitinib, erlotinib, and afatinib with the LUX-Lung 3 19 and LUX-Lung 6 20 studies, demonstrating improvements in overall survival in patients with EGFR exon 19 deletion-positive tumors. Figure 1 summarizes the most clinically relevant EGFR mutations and pictorially demonstrates the distinct molecular targets of various EGFR inhibitors.
EGFR T790M as a resistance mechanism to first-and secondgeneration EGFR TKIs
While first-and second-generation EGFR TKIs represent a prominent example of the clinical benefits targeted-therapy approaches can have on advanced oncogene-driven malignancies, the emergence of acquired resistance to these agents has prevented them from achieving long-term durable control of EGFR-mutant lung cancer. While approximately 60%-80% of patients with EGFR-mutant tumors initially respond to first-and second-generation EGFR TKIs with significant improvement in both objective response rates and progressionfree survival compared to upfront platinum-containing chemotherapy regimens, resistance invariably develops, with a median progression-free survival of 9-16 months.
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EGFR T790M -secrets revealed
First described in 2005, the most common mechanism of acquired resistance to first-and second-generation EGFR TKIs involves a threonine-methionine amino acid substitution at T790M of EGFR. 7, 21 Approximately 60% of patients treated with first-and second-generation EGFR TKIs harbor EGFR T790M mutations at the time of progression. 22 In rare cases, EGFR T790M is reported as a germ-line alteration leading to a high lifetime risk of lung cancer, 23 and recent research suggests that certain NSCLC tumors harbor genetically heterogeneous subclones with the EGFR T790M mutation at disease onset, instead of developing T790M de novo. Additionally, a subset of cells that are initially EGFR T790M-negative and survive EGFR TKI treatment can subsequently acquire EGFR T790M for a fitness advantage, representing a population of drug-tolerant cells that can evolve further acquired resistance mechanisms in the context of drug-related selective pressure. 24 Several studies suggest that EGFR T790M-positive lung cancers tend to have more indolent progression and better prognosis compared to EGFR T790M-negative lung cancers, 25, 26 as the development of EGFR T790M may require less complex genetic and molecular changes compared to other resistance mechanisms. The biochemical mechanisms of EGFR T790M-associated resistance are likely multifactorial, including the popular "gatekeeper" hypothesis, which stipulates that there is steric clash between the larger methionine moiety (compared to threonine) on the gatekeeper side chain of EGFR T790M and the aniline moiety of first-generation EGFR TKIs. Other mechanisms include drastically increased ATPbinding affinity for EGFR T790M, alterations in the catalytic domain, and changes in overall conformational dynamics. 27 In contrast to other targetable kinases, such as ABL in chronic myeloid leukemia and ALK in ALK translocation-positive lung adenocarcinomas, in which a variety of second-site mutations can lead to resistance, 28 EGFR T790M remains the only validated and relevant second-site resistance mutation for EGFR, as all other secondary mutations have been noted only in occasional case reports. This key dependence on T790M-mediated acquired resistance has allowed focused research into the development of T790M-targeting inhibitors. 29, 30 Studies with afatinib have focused on patients with clinically defined acquired resistance to first-generation EGFR TKIs. In the pivotal LUX-Lung 1 study, a significant prolongation of progression-free survival was noted compared to placebo, along with a 7% response rate; however, this did not translate into improved overall survival. 6 Similarly, other second-generation EGFR TKIs did not reach critical milestones in development for this space. 31 The reason for the poor efficacy of afatinib and similar drugs in this setting is more related to excessive potency against wild-type EGFR leading to substantial epithelium-based toxicities, rather than lack of efficacy against the mutant form. Principally, the therapeutic window in this setting is not sufficiently wide for significant clinical impact.
Based on transgenic mouse studies with preclinical models of EGFR T790M-mutated lung adenocarcinomas, 32 the combination of afatinib and cetuximab was developed to provide needed synergy for enhanced clinical benefit. While studies of this combination demonstrated a significant improvement in response rates to more than 30% without significant differences between cases with or without documented EGFR T790M, 33 the excessive toxicity of the combination has limited overall enthusiasm for further development.
Targeting EGFR T790M with thirdgeneration EGFR TKIs
Recognizing the limitations of second-generation EGFR TKIs, third-generation EGFR TKIs were developed specifically to target EGFR T790M and spare wild-type EGFR, thereby achieving much broader therapeutic windows compared to second-generation agents. Two compoundsosimertinib (AZD9291) and rociletinib (CO-1686) -were the first to be introduced to the clinic. 34, 35 Both are irreversible covalent inhibitors of EGFR via binding to C797, allowing them to achieve sustained and complete EGFR inhibition, even in the presence of high intracellular concentrations of ATP, unlike gefitinib and erlotinib. Both osimertinib and rociletinib bind more avidly to EGFR T790M mutants than wild-type EGFR, mitigating some of the off-target effects associated with afatinib.
27 Table 1 summarizes the relative differences in activity of multiple EGFR-directed therapies against various EGFR mutations.
Osimertinib (AZD9291) is a monoanilinopyrimidine compound that has little activity against wild-type EGFR, but irreversibly and very potently inhibits EGFR T790M and other common mutated forms of EGFR. It covalently binds cysteine 797 of EGFR, and has activity against some other kinases that harbor a cysteine residue in their analogous kinase domain, such as ErbB2, ErbB4, and BLK (formerly called BTK). Two circulating active metabolites, a desmethylindole analogue, AZ5104, and an N-demethylated analogue, AZ7550, have been observed in both preclinical and clinical settings, with significant dose-dependent tumor regression in NSCLC cell lines with activating mutations of EGFR and in tumor xenograft models. 27 Despite tremendous initial excitement, clinical development of rociletinib was abruptly halted, due to high numbers of serious adverse events, including hyperglycemia and QT prolongation in clinical trials, which have been attributed to cross-reactivity with IGF1R. 36, 37 Osimertinib has a more favorable side-effect profile without cross-reactivity with IGF1R. Initial studies of osimertinib in an extended Phase I study of 253 patients with EGFR-mutated lung adenocarcinoma and resistance to prior EGFR TKI therapy demonstrated good tolerance across dose-escalation cohorts (20-240 mg) without identified dose-limiting toxicities. 38 Five doseexpansion cohorts demonstrated an objective response rate 
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EGFR T790M -secrets revealed of 51%, and in patients with documented EGFR T790M this was even higher, at 61%, with progression-free survival of 9.6 months (compared to 21% response rate for EGFR T790M-negative patients and progression-free survival of 2.8 months). Subsequently, based on similar activity in the AURA extension and AURA2 studies, 39 osimertinib obtained an accelerated US Food and Drug Administration (FDA) indication for the treatment of metastatic EGFR T790M mutation-positive NSCLC in patients who have progressed on or after EGFR TKI therapy. 40 In both single-arm studies, osimertinib was administered at 80 mg orally once daily, and objective response rates of 57% and 61% were noted in the AURA extension study and AURA2, respectively. Most observed adverse events were mild, and included diarrhea, rash, dry skin, and nail toxicities. Pneumonitis remains a concern like other EGFR TKIs, affecting a small percentage of patients (3.3% in these two studies). Osimertinib is now the mainstay of therapy for EGFR T790M mutation-positive NSCLC.
In 2016, the AURA3 Phase III trial demonstrated that in patients with EGFR T790M-positive advanced NSCLC who had disease progression after first-line EGFR TKI therapy, the median duration of progression-free survival was significantly longer with osimertinib than with platinum-containing chemotherapy (cisplatin or carboplatin) plus pemetrexed (10.1 months vs 4.4 months, HR 0.3, 95% CI 0.23-0.41; P<0.001), with significantly longer median duration of progression-free survival in the subset of patients with central nervous system metastases (8.5 months vs 4.2 months, HR 0.32, 95% CI 0.21-0.49). The objective response rate was also significantly better with osimertinib (71%, 95% CI 65%-76%) than with platinum-containing chemotherapy plus pemetrexed (31%, 95% CI 24%-40%) (OR 5.39, 95% CI 3.47-8.48; P<0.001). In addition, the proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum-containing chemotherapy plus pemetrexed (47%). 41 These outstanding results led to full FDA approval of osimertinib in 2017.
Many ongoing studies are exploring combinations of osimertinib with other agents that have established synergy in the management of advanced NSCLC, including bevacizumab, ramucirumab, and necitumumab, as well as combinations with other agents affecting pathways of resistance, such as MET inhibition and immune-checkpoint inhibition. While the relatively atoxic nature of osimertinib makes it an ideal partner for drug combinations, combination studies of osimertinib and durvalumab have demonstrated an unexpectedly high rate of interstitial lung disease. 42 A range of clinical studies featuring osimertinib in combination with other agents are highlighted in Table 2 .
Other third-generation EGFR inhibitors in development
Olmutinib (HM61713) is an irreversible EGFR TKI that (like osimertinib) binds EGFR C797 and has preferential activity against all mutant forms of EGFR, including EGFR T790M. In a Phase I/II study, 800 mg/day was defined to be the recommended dose for further studies; at this dose level, olmutinib appears generally well tolerated, with rare cases of interstitial lung disease, but no documented cases of hyperglycemia. 43 A total of 76 EGFR T790M-positive patients received therapy at the 800 mg/day dose level, with an objective response rate of 54%. Central nervous system activity was also noted, and based on these promising results, olmutinib gained approval 
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EGFR T790M -secrets revealed in South Korea in 2016. Current studies in the second-line (ELUXA 2) and frontline setting (ELUXA 1) are ongoing or recently completed. However, development of this drug in the US is currently on hold. Nazartinib (EGF816) is another potent and selective EGFR-mutant inhibitor with irreversible binding to EGFR C797. 44 Early-phase studies demonstrated promising activity, with an objective response rate of 46.9% and reported side effects of rash and diarrhea. Ongoing studies are exploring combination strategies with MET inhibitors and immunecheckpoint inhibitors.
ASP8273, which has mostly been developed in Asia, is another selective and potent third-generation EGFR inhibitor that has demonstrated good tolerance and excellent activity in early-phase studies, with an objective response rate of 64% in 70 EGFR T790M-positive patients treated at a dose of 300 mg/day. Current development focuses on first-line indication, with an ongoing pivotal Phase III study (SOLAR) comparing ASP8273 to gefitinib/erlotinib in treatment-naive patients with EGFR-mutation positive NSCLC.
Methods of detecting EGFR T790M
Given the high objective response rates of EGFR T790M mutation-positive lung cancers to osimertinib, it is crucial to accurately identify tumors that harbor EGFR T790M. Until recently, the standard of care for detecting EGFR T790M at the time of disease progression on EGFR TKI therapy was via tissue biopsy followed by sequencing using a range of testing platforms with differing sensitivities for the detection of subclonal presence of mutations. However, invasive biopsies cannot be performed in all patients (eg, tumors in anatomic locations that are difficult to access, very small metastatic lesions), and are associated with significant risks, such as bleeding, lung injury, and pneumothoraces. They can also inadequately sample genomically heterogeneous tumors, and might not accurately reflect tumor heterogeneity within a single patient. In addition, a single-biopsy procedure may provide insufficient material for the required battery of genetic and immunochemistry assays. With increasing recognition that serial molecular assessments are necessary to tailor treatments appropriately for lung cancer throughout the disease course, 22 serial invasive biopsies represent a significant practical barrier in clinical care.
To address this problem directly, clinical development of noninvasive methods to detect genomic aberrations accurately is active in a wide range of tumor types, including isolation of circulating tumor cells (CTCs) and both plasma-based and urine-based ctDNA assays. While all cells shed short (usually 150-170 base pairs in length) doublestranded DNA fragments called cfDNA into the systemic circulation, 45, 46 malignant cells from primary and metastatic tumors shed CTCs and ctDNA, providing potential sources of systemic tumor-derived genetic material that carries mutations representative of tumor biology. 47 In fact, ctDNA may more accurately reflect tumor heterogeneity within a given patient, and multiple studies have demonstrated that increasing solid-tumor burden is associated with higher detected levels of cfDNA and ctDNA. While capturing an adequate numbers of CTCs from blood samples has been a difficult technical challenge, more sensitive microfluidic-based platforms 48 have further opened the possibility of noninvasive blood-based testing in combination with modern genotyping assays. In patients with advanced NSCLC, ctDNA-detection rates ranging from 80% to over 95% have been reported using current detection assays. 49, 50 With rapid progress in ctDNAbased technologies, multiple plasma-based, urine-based, and cerebrospinal fluid-based testing platforms have entered the clinical arena over the last few years. There are many platforms available or in active development based on droplet digital polymerase chain reaction and massively parallel DNA sequencing, otherwise known as next-generation sequencing, including cancer personalized profiling by deep sequencing, which can simultaneously detect insertions, deletions, rearrangements, single-nucleotide variants, and somatic copynumber alterations to examine a diverse array of potential resistance mechanisms. 51 Key registration research utilized the Cobas EGFR-mutation test, which uses tumor tissue or plasma to detect 42 mutations in exons 18-21 of the EGFR gene, including T790M. 52 In a prospective, multicenter exploratory analysis of 40 patients with EGFR-mutant tumors that had progressed on first-or second-generation EGFR TKIs, blood samples were drawn for CTC and ctDNA analyses at the same time as tumor biopsy to assess EGFR T790M test characteristics and concordance among the three diagnostic modalities. Interestingly, no clear "gold standard" emerged, and mutation data among tissue-based and blood-based analyses provided nonoverlapping and complementary information, as the noninvasive blood-based analyses identified the EGFR T790M mutation in 14 (35%) of patients who had negative or indeterminate invasive tumor biopsies. 53 Further validation studies are clearly warranted, but it appears that the concurrent use of noninvasive blood-based analyses may help provide a more complete assessment of the biology of a given patient's EGFR-mutant tumors. Indeed, FDA approval for the tissue and blood-based Cobas EGFR-mutation ctDNA 
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Ko et al assay has been secured in 2016, based on the aforementioned studies. Figure 2 provides a brief flowchart that demonstrates how ctDNA testing could be incorporated into the clinical management workflow for advanced NSCLC.
Acquired resistance to EGFR
T790M-targeting TKIs
Unfortunately, novel acquired resistance mechanisms are emerging in specific response to EGFR T790M-directed therapy as well. For patients with EGFR T790M-positive lung cancer treated with osimertinib, progression-free survival usually ranges from 10 to 12 months. Tumor samples from patients treated with osimertinib and rociletinib during Phase I studies revealed several distinct acquired-resistance mechanisms, including the key EGFR C797S mutation, which drastically reduces the efficacy of all third-generation EGFR inhibitors. 51, 54 The detected frequency of C797S varied from study to study with different molecular monitoring methods, but it has been reported to be as high as 22%. Intriguingly, the allelic context of the occurrence of C797S might have treatment implications. 55 If EGFR C797S occurs in trans with EGFR T790M on a different allele, the cells might retain sensitivity to a combination of first-and third-generation EGFR inhibitors. If the mutations are on the same allele in cis, high-level resistance is expected against all currently used EGFR TKIs; recent data suggest that most EGFR C797S mutations are occurring in cis. While tissue-based EGFR sequencing remains the standard, ctDNA approaches in this context are gaining clear importance. Since ctDNA exists typically as 150-170 base-pair fragments, the proximity of EGFR T790 and EGFR C797 allows these allelic relationships to be readily assessed. Interestingly, this EGFR C797S-resistance mutation is analogous to the recently described BTK-resistance mutation, C481S, which arises in the context of the BTK inhibitor ibrutinib in chronic lymphocytic leukemia. 56 Besides EGFR C797S, multiple other resistance mechanisms to osimertinib therapy have been documented in case reports and case series, mirroring what has been reported with first-generation EGFR inhibitors. 57 As anticipated, MET amplification, SC transformation, and downstream mutations in BRAF and PI3K have been noted. In addition to C797S, other EGFR mutations such as L792F might represent alternative resistance mechanisms. ctDNA platforms greatly accelerate the discovery of these mechanisms, and need to be integrated into ongoing studies. 58, 59 In addition, 
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EGFR T790M -secrets revealed an interesting and recurrent observation has been that upon the development of resistance to EGFR T790M-directed therapy, the original T790M-mutated clone often becomes undetectable, highlighting some potential for retreatment with earlier-generation drugs for certain patients.
Overcoming resistance to EGFR
T790M-targeting TKIs
Since all currently FDA-approved EGFR TKIs target the ATP site of EGFR, a promising drug-discovery strategy involves the development of allosteric inhibitors that selectively target drug-resistant EGFR mutants while binding less avidly to wild-type EGFR. One such lead compound, EAI045, binds an allosteric site on the inactive conformation of EGFR and inhibits L858R/T790M-mutant EGFR with low-nanomolar potency (but not exon 19 deletion/T790M). 60 However, as a single agent, EAI045 is ineffective in targeting EGFR asymmetric dimers and cannot block EGFR-driven cell proliferation. In combination with cetuximab, a recombinant human/ mouse chimeric monoclonal antibody, which binds EGFR and prevents EGFR dimerization by competitively inhibiting the binding of cognate ligands, EAI045 effectively blocks EGFR-driven cell proliferation in mouse models of lung cancer driven by both L858R/T790M EGFR and L858R/ T790M/C797S EGFR. Analogous to prior discussions with afatinib, resistant cells with T790M/C797S EGFR remain partially sensitive to cetuximab because of the disruption of EGFR dimerization. The combination of EAI045 and cetuximab demonstrated significant synergy in these elegant studies, and represents a possible approach to circumventing acquired resistance mediated by EGFR C797S.
Another promising approach utilizes the combination of the highly potent and selective ALK/EGFR T790M inhibitor brigatinib, along with cetuximab. 61 While brigatinib has demonstrated modest efficacy as a single agent in early studies focused on EGFR T790M-positive patients, in an in vitro drug-screening Ba/F3 cell-line model it had the best efficacy among all screened compounds against triple-EGFR mutation-positive cells and structural prediction models suggest that this might be related to a better fit without steric crowding in the context of T790M and/ or C797S compared to other EGFR inhibitors. While the in vitro efficacy of brigatinib monotherapy might not be clinically meaningful, given high required concentrations, concurrent treatment with cetuximab led to substantial synergy, yielding a potentially meaningful IC 50 in the hundred-nanomolar range.
Conclusion
Since the original discovery of the pivotal EGFR T790M mutation driving acquired resistance in most EGFR-mutated lung adenocarcinomas exposed to first-or second-generation EGFR TKI therapy, a tremendous amount has been learned about the mechanism and biology of resistance. Tissue-and ctDNA-based testing for EGFR T790M has now become the standard of care. The high frequency of this key gatekeeper mutation permitted successful development of effective drugs specifically targeting this molecular aberration, yielding highly potent and safe drugs, such as osimertinib, that are extending the benefits of EGFR-directed therapy. Osimertinib will likely move into earlier lines of therapy, and rational drug combinations are now being developed to overcome and prevent such molecularly driven resistance. Lastly, the paradigm shift defined by acquired resistance via EGFR T790M has allowed rapid evolution of analogous knowledge for third-generation EGFR inhibitors. These lessons will continue to provide valuable insight into many other molecularly defined subsets of patients with a wide range of solid and hematological malignancies.
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